CheckMyRecalls

McKesson recalls Inflectra (infliximab-dyyb)

Published
5 Feb 2025
Units affected
192 vials
Agency
FDA
Country
United States

The hazard

CGMP Deviations: Product intended for quarantine was inadvertently distributed.

Classification: Class II — this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.

What to do

Do not stop a prescribed medicine without talking to your doctor or pharmacist first. Ask them about a replacement, and return the recalled product to the pharmacy.

  • Check the lot number on the box or bottle.
  • Talk to your pharmacist or doctor before stopping any prescribed medicine.
  • Return the product to the pharmacy for safe disposal.
Read the official FDA notice

Product details

Inflectra (infliximab-dyyb), For injection, 100mg per vial, packaged in 10 mL single-dose vial, Rx only, Mfd by: CELLTRION, INC, Dist. by: Pfizer Labs, Division of Pfizer Inc., New York, NY 10001, NDC 0069-0809-01

Brand / company
McKesson
Codes / lots
Lot# 04647349, Exp Date 5/31/2029
Distribution
Nationwide USA
Recall status
Ongoing

Source: U.S. Food and Drug Administration, published 5 Feb 2025. CheckMyRecalls reproduces the official notice in summary; always confirm the details with the original notice.